Celcuity's phase 3 VIKTORIA-2 trial of gedatolisib as a first-line treatment for HR+/HER2- advanced breast cancer expanding to include endocrine-sensitive patients

Published: 2026-05-14 08:18:49 ET CELC

Published on 05/14/2026 at 08:18 am EDT